Fig 1: POM appearances of LC biosensor cells after incubation of HER-2 Ab immobilized surface with 0.01 IU (a) CA125, (b) CA19-9, (c) CEA, (d) CA15-3, (e) PSA, and (f) 0.01 ng/mL HER-2 + 0.01 IU CA125, (g) 0.01 ng/mL HER-2 + 0.01 IU CA19-9, (h) 0.01 ng/mL HER-2 + 0.01 IU CEA, (i) 0.01 ng/mL HER-2 + 0.01 IU CA15-3, (j) 0.01 ng/mL HER-2 + 0.01 IU PSA, at equal ratio, (k) mixture of proteins (0.01 IU CA125, CA19-9, CEA, CA15-3, PSA and 0.01 ng/mL HER-2 at equal ratio), and (l) 0.01 ng/mL HER-2. Scale bar: 100 µm.
Fig 2: POM appearances of LC biosensors cells in response to HER-2 protein at the concentration of: (a) 0, (b) 10–6, (c) 10–5, (d) 10–4, (e) 10–3, (f) 10–2, (g) 10–1, (h) 1, (i) 10 and (j) 102 ng/mL. Scale bar: 50 µm.
Fig 3: POM appearances of LC biosensor cells after incubation of HER-2 Ab immobilized surface with untreated serum (a) sample 1, (b) sample 2, (c) sample 3, (d) sample 4, (e) sample 5, and (f) sample 6 of six breast cancer patients. Scale bar: 50 µm.
Fig 4: The calibration curve of the mean GI of the POM appearance via the logarithm concentration of the HER-2 protein.
Fig 5: Correlated histograms of average GI of 0.01 ng/mL of HER-2 protein, 0.01 IU of other interferences proteins, the combination of HER-2 with interferences proteins, and the mixture of all proteins.
Supplier Page from Abcam for Recombinant human ErbB2 / HER2 protein (Active)